Riskpilot← Back to searchSign inGet full accessNeuraxio AB
ABActiveOrg 5593003931Tallholmsvägen 285Hospital activities · NACE 8610Est. 20210 employees
Revenue 2024
SEK 274K
-88% vs 2023
EBITDA margin
-46.0%
-125% vs 2023
Equity ratio
30.4%
Financial strength
Net profit 2024
SEK 1K
-100% vs 2023
| Revenue | SEK 274K | -88% |
| EBITDA | SEK -126K | -125% |
| Net profit | SEK 1K | -100% |
| Total assets | SEK 339K | -75% |
| Equity | SEK 103K | -74% |
| Employees | 0 | — |
Legal name
Neuraxio AB
Org number
5593003931
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
5 februari 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Konsultverksamhet, kursverksamhet och utbildning inom neurokirurgi samt ortopedisk fysioterapi.
Address
Tallholmsvägen 285
Email
rafael.holmgren@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 67 | 528 | 2 207 | 274 |
| Staff expenses | — | — | — | — |
| EBITDA | 6 | 466 | 511 | −126 |
| Depreciation & amort. | −0 | −0 | −6 | −7 |
| EBIT | 6 | 466 | 505 | −133 |
| Net financials | — | — | — | −3 |
| Profit before tax | 6 | 351 | 374 | 8 |
| Tax | −1 | −73 | −82 | −7 |
| Net profit | 5 | 278 | 292 | 1 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 40 | 625 | 1 346 | 339 |
| Equity | 30 | 307 | 400 | 103 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 203 | 701 | 136 |
| Total debt | 10 | 203 | 701 | 136 |
EBITDA margin
-46.0%
This company
15.8%
Market median
-391% vs market
20212024
Equity ratio
30.4%
This company
38.2%
Market median
+20% vs market
20212024
Return on equity
1.0%
This company
18.4%
Market median
-95% vs market
20212024
Net profit margin
0.4%
This company
8.1%
Market median
-95% vs market
20212024
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20212024
Debt / equity
2.29×
This company
0.62×
Market median
-269% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neuraxio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Teresa Maritha Holmgren | Deputy Chief Executive Officer | 0 companies |
| Anders Robert Holmgren | Deputy Board Member | 0 companies |
| Adam David Holmgren | Deputy Board Member | 0 companies |
| Rafael Bohdan Holmgren | Chairman | 0 companies |